TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05360888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tools for Life
Description: Tools for Life focuses on empowering youth to learn more about their culture and their identity.
Study: NCT05897619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Maya Perinatal Cognitive Behavioral Skills App
Description: The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
Study: NCT05274763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spiritual Therapy
Description: Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
Study: NCT05826093

Intervention type: PROCEDURE
Intervention: Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)
Description: US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
Study: NCT05538338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma Intrauterine infusion
Description: an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline Intrauterine infusion
Description: an intrauterine infusion of normal saline will be administered to this group of participants
Study: NCT04790643

Intervention type: OTHER
Intervention: Exercise-based cardiac rehabilitation program (Stage 1)
Description: In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).

Intervention type: OTHER
Intervention: Exercise-based cardiac rehabilitation program (Stage 2)
Description: In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
Study: NCT05957146

Intervention type: DEVICE
Intervention: Routine hemodialysis
Description: * Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin.
Study: NCT05360888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tools for Life + MISN
Description: Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
Study: NCT05988931

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Program + App
Description: Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Program + App + Text Messages
Description: Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
Study: NCT05653752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202
Description: YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes.
Study: NCT05094037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable cam walker boot
Description: Standard of care device given to diabetic foot ulcer patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable cam walker boot
Description: Standard of care device given to diabetic foot ulcer patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
Study: NCT05196932

Intervention type: DEVICE
Intervention: Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Description: A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system.
Study: NCT06556810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atibuclimab (IC14)
Description: Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
Study: NCT04894578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse distal metatarsal minimal-invasive osteotomy
Description: minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tarsometatarsal fusion
Description: open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
Study: NCT06449235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylureas
Description: Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs.
Study: NCT05922280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subtalar and talo-crural mobilization
Description: Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International Working Group of the Diabetic Foot care guidelines
Description: Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension
Study: NCT06455761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-NI-FAPI04
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI/18F-FDG
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study: NCT04857190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker Flex-it Directional Stylet
Description: Parker Flex-it Directional Stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Malleable Stylet
Description: Conventional Malleable Stylet
Study: NCT05878925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma
Description: The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
Study: NCT06530524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Injection of onabotulinumtoxinA into the at-risk major salivary glands

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of normal saline into the at-risk major salivary glands
Study: NCT05030935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App
Description: In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
Study: NCT04890522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triprilimab(JS001)
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab(JS001)
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study: NCT04532151

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive skin imaging assessment
Description: Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive skin imaging assessment
Description: Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive skin imaging assessment
Description: Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable.
Study: NCT06292533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
Study: NCT04384679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrophilic polymer and potassium ferrate powder
Description: Application with pressure until hemostasis is achieved
Study: NCT06480071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline, 0.05% Nasal Spray
Description: 2 sprays each nostril before the excercise test.
Study: NCT06162026

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RACS app
Description: risk assessment questions, symbol matching task, voice tasks
Study: NCT04604730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary anastomosis without protective stoma
Description: Primary anastomosis without protective stoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anastomosis with protective stoma
Description: Anastomosis with protective stoma
Study: NCT05699460

Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study.

Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study.
Study: NCT04877782

Intervention type: DEVICE
Intervention: Transcutaneous vagus verne stimulation
Description: Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
Study: NCT05057949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotinib
Description: Larotinib Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotinib
Description: Larotinib Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Capsules
Study: NCT06229366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Ac-225]-PSMA-62 (mCRPC)
Description: Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Ac-225]-PSMA-62 (OmHSPC)
Description: Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles.
Study: NCT05157282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TESS
Description: Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TESS
Description: Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TESS
Description: Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be instructed to do repetitive motor movements with their arm or hand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-TESS
Description: Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study: NCT05161039

Intervention type: DEVICE
Group type: OTHER
Intervention: Serranator
Description: Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular

Intervention type: DEVICE
Group type: OTHER
Intervention: POBA
Description: Plain balloon angioplasty device
Study: NCT06159101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX13
Description: A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-sourced ipilimumab
Description: A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced ipilimumab group
Description: A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced ipilimumab group
Description: A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
Study: NCT05157282

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-TESS
Description: Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study: NCT05279937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 50% Intravenous Solution
Description: 5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% Injectable Solution
Description: 10mL of 1% Lidocaine (Control)
Study: NCT05456100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing
Description: Expressive writing involves emotional disclosure writing over four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factual Writing
Description: Factual writing involves writing facts about cancer treatment and experiences over four weeks.
Study: NCT05269849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
Study: NCT06559137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
Study: NCT05166889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Administered subcutaneously tozorakimab Dose 2 through Week 52.
Study: NCT06649903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: high speed low amplitude neck manipulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteopathy
Description: the stomach and liver technique was applied